Mechanism of erythropoietin-induced hypertension
Abstract
Chronic administration of erythropoietin (EPO) is associated with an increase in arterial blood pressure in patients and animals with chronic renal failure (CRF). Several mechanisms have been considered in the pathogenesis of EPO-induced hypertension. These include the possible role of the rise of hematocrit and erythrocyte mass, changes in production or sensitivity to endogenous vasopressors, alterations in vascular smooth-muscle ionic milieu, dysregulation of production or responsiveness to endogenous vasodilatory factors, a direct vasopressor action of EPO, and finally arterial remodeling through stimulation of vascular cell growth.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Long-term use of erythropoietin promotes vascular smooth muscle cell growth, vascular remodeling, and medial hypertrophy, with maintained elevated blood pressure.
“Long-term use of erythropoietin promotes vascular smooth muscle cell growth, vascular remodeling, and medial hypertrophy, with maintained elevated BP.222,223”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [222]
Cites
Hypertension : pathophysiology, diagnosis, and management
Laragh, J. H., & Brenner, B. M. (1995) · Raven Press eBooks · Cited by 1,935 · see citing works
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930 · see citing works
Polar secretion of endothelin-1 by cultured endothelial cells.
Wagner, O. F., Christ, G., Wojta, J., Vierhapper, H., Parzer, S. B., Nowotny, P., Schneider, B., Waldhäusl, W. K., & Binder, B. R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41966-7 · Cited by 637 · see citing works
Raine, A. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90293-0 · Cited by 257 · see citing works
Recombinant human erythropoietin stimulates angiogenesis in vitro
Carlini, R. G., Reyes, A. A., & Rothstein, M. (1995) · Kidney International · doi:10.1038/ki.1995.113 · Cited by 248 · see citing works
Ca2+ localization and sensitivity in vascular smooth muscle
Karaki, H. (1989) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(89)90066-7 · Cited by 236 · see citing works
Neff, M. S., Kim, K. E., Persoff, M., et al. (1971) · Circulation · doi:10.1161/01.cir.43.6.876 · Cited by 221 · see citing works
DERMATITIS CAUSED BY PENICILLIN IN MILK
Vickers, H. R., Bagratuni, L., & Alexander, S. (1958) · The Lancet · doi:10.1016/s0140-6736(58)90972-3 · Cited by 202 · see citing works
Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells
Carlini, R. G., Dusso, A., Obialo, C. I., Alvarez, U., & Rothstein, M. (1993) · Kidney International · doi:10.1038/ki.1993.142 · Cited by 194 · see citing works
PLATELET PRESERVATION BY APROTININ DURING CARDIOPULMONARY BYPASS
van Oeveren, W., Eijsman, L., Roozendaal, K. J., et al. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91437-7 · Cited by 193 · see citing works
Lincoln, T., & Cornwell, T. L. (2008) · Blood Vessels · doi:10.1159/000158852 · Cited by 187 · see citing works
Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels
Heidenreich, S., Rahn, K.-H., & Zidek, W. (1991) · Kidney International · doi:10.1038/ki.1991.31 · Cited by 183 · see citing works
Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH
Vaziri, N. D., Ni, Z., Wang, X. Q., Oveisi, F., & Zhou, X. (1998) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1998.274.4.f642 · Cited by 173 · see citing works
Self-citationResnick, L. M. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90290-r · Cited by 146 · see citing works
Jackson, R. H., Craft, A. W., Sibert, J. R., et al. (1980) · The Lancet · doi:10.1016/s0140-6736(80)90524-3 · Cited by 144 · see citing works
Carlini, R. G., Obialo, C. I., & Rothstein, M. (1993) · American Journal of Hypertension · doi:10.1093/ajh/6.2.103 · Cited by 123 · see citing works
Effects of erythropoietin on blood pressure.
Raine, A. E. G., & Roger, S. D. (1991) · PubMed · Cited by 115 · see citing works
Bode‐Böger, S. M., Böger, R. H., Kühn, M., Radermacher, J., & Frölich, J. C. (1996) · Kidney International · doi:10.1038/ki.1996.435 · Cited by 113 · see citing works
Kusunoki, M., Kimura, K., Nakamura, M., Isaka, Y., Yoneda, S., & Abe, H. (1981) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1981.45 · Cited by 100 · see citing works
Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin.
Abraham, P. A., & Macres, M. G. (1991) · Journal of the American Society of Nephrology · doi:10.1681/asn.v24927 · Cited by 100 · see citing works
Erythropoietin: Physiologic and Pharmacologic Aspects
Fisher, J. W. (1997) · Experimental Biology and Medicine · doi:10.3181/00379727-216-44183 · Cited by 96 · see citing works
Hypertension Following Erythropoietin Therapy in Anemic Hemodialysis Patients
Buckner, F. S., Eschbach, J. W., Haley, N., et al. (1990) · American Journal of Hypertension · doi:10.1093/ajh/3.12.947 · Cited by 92 · see citing works
Vaziri, N. D., Zhou, X., Naqvi, F., Smith, J., Oveisi, F., Wang, Z. Q., & Purdy, R. E. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.1.e113 · Cited by 90 · see citing works
Self-citationAmmarguellat, F., Gogusev, J., & Drüeke, T. B. (1996) · Nephrology Dialysis Transplantation · doi:10.1093/oxfordjournals.ndt.a027361 · Cited by 89 · see citing works
Erythropoietin receptor-operated Ca2+ channels: Activation by phospholipase C-γ1
Marrero, M. B., Venema, R. C., Ma, H., Ling, B. N., & Eaton, D. C. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00887.x · Cited by 85 · see citing works
Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure
Hand, M. F., Haynes, W. G., Johnstone, H. A., Anderton, J. L., & Webb, D. J. (1995) · Kidney International · doi:10.1038/ki.1995.354 · Cited by 79 · see citing works
In vivo and in vitro pressor effects of erythropoietin in rats
Vaziri, N. D., Zhou, X., Smith, J., Oveisi, F., Baldwin, K., & Purdy, R. E. (1995) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1995.269.6.f838 · Cited by 76 · see citing works
Self-citationErythropoietin for End-Stage Renal Disease
Adamson, J. W., & Eschbach, J. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390910 · Cited by 73 · see citing works
Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems
Eggena, P., Willsey, P., Jamgotchian, N. J., et al. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.261.5.e642 · Cited by 73 · see citing works
Kaupke, C. J., Kim, S., & Vaziri, N. D. (1994) · Journal of the American Society of Nephrology · doi:10.1681/asn.v4111874 · Cited by 67 · see citing works
Self-citationBlood Pressure Changes during Treatment with Recombinant Human Erythropoietin
Samtleben, W., Baldamus, C. A., Bömmer, J., et al. (2015) · Contributions to nephrology · doi:10.1159/000416009 · Cited by 63 · see citing works
Nitric Oxide Metabolism in Erythropoietin-Induced Hypertension
Ni, Z., Wang, X. Q., & Vaziri, N. D. (1998) · Hypertension · doi:10.1161/01.hyp.32.4.724 · Cited by 62 · see citing works
Self-citationGeet, C. V., Damme‐Lombaerts, R. V., Vanrusselt, M., et al. (1990) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1647144 · Cited by 58 · see citing works
Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells
Neusser, M., Tepel, M., & Zidek, W. (1993) · Cardiovascular Research · doi:10.1093/cvr/27.7.1233 · Cited by 54 · see citing works
Takahashi, K., Totsune, K., Imai, Y., et al. (1993) · Clinical Science · doi:10.1042/cs0840047 · Cited by 54 · see citing works
Bode‐Böger, S. M., Böger, R. H., Kühn, M., et al. (1992) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199204002-00009 · Cited by 52 · see citing works
Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients.
Lebel, M., Kingma, I., Grose, J. H., & Langlois, S. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v9197 · Cited by 45 · see citing works
Gogusev, J., Zhu, D. L., Hérembert, T., et al. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1325 · Cited by 42 · see citing works
Steffen, H., Brunner, R., M�ller, R., et al. (2015) · Contributions to nephrology · doi:10.1159/000417905 · Cited by 40 · see citing works
Castillo, D. D., Raij, L. R., Shultz, P. J., et al. (1995) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/10.4.505 · Cited by 35 · see citing works
Decreased intracellular free magnesium in erythrocytes of spontaneously hypertensive rats
Matuura, T., Kohno, M., Kanayama, Y., et al. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90352-4 · Cited by 34 · see citing works
BLOOD PRESSURE, ERYTHROPOIETIN, AND NITRIC OXIDE
Martin, J. F., & Moncada, S. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91438-9 · Cited by 32 · see citing works
Zhou, X., Pandian, D. V., Wang, X. Q., et al. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v86901 · Cited by 31 · see citing works
Mechanisms of Erythropoietin Signal Transduction: Involvement of Calcium Channels
Miller, B. A., & Cheung, J. Y. (1994) · Experimental Biology and Medicine · doi:10.3181/00379727-206-43756 · Cited by 31 · see citing works
Vasdev, S., Thompson, P., Triggle, C. R., et al. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(88)90696-1 · Cited by 30 · see citing works
Lai, K. N., Lui, S. F., Leung, J. C. K., et al. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000186302 · Cited by 29 · see citing works
Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue
Katoh, K., Mizuno, K., Hashimoto, S., et al. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00842-6 · Cited by 27 · see citing works
Lack of a Fast‐Acting Effect of Erythropoietin on Arterial Blood Pressure and Endothelin Level
Hon, G., Vaziri, N. D., Kaupke, C. J., et al. (1995) · Artificial Organs · doi:10.1111/j.1525-1594.1995.tb02309.x · Cited by 18 · see citing works
Self-citationPlasma Na-K Atpase Inhibitor Activity and Intracellular Ions during Hemodialysis
Krzesinski, J. M., Du, F.-M., Pequeux, M. L., et al. (1993) · The International Journal of Artificial Organs · doi:10.1177/039139889301600106 · Cited by 7 · see citing works
Cytosolic Ionized Magnesium Concentration in End-Stage Renal Disease
Kaupke, C. J., Zhou, X. J., & Vaziri, N. D. (1993) · ASAIO Journal · doi:10.1097/00002480-199307000-00095 · Cited by 5 · see citing works
Self-citationCytosolic Ionized Magnesium Concentration in End-Stage Renal Disease
Kaupke, C. J., Zhou, X. J., & Vaziri, N. D. (1993) · ASAIO Journal · doi:10.1097/00002480-199339030-00088 · Cited by 2 · see citing works
Self-citationVaziri, N. D. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)80161-7 · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153 · see citing works
- Authors
- Vaziri, N. D.
- Affiliations
- University of California, Irvine (US)
- Corresponding author
- Vaziri, Nosratola D.
- ORCID
- Vaziri, Nosratola D.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 1999-05
- Volume
- 33
- Issue
- 5
- Pages
- 821-828
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W1967972391
- Cited by
- 154
- References
- 52
- Citations by year
- 2025: 2 · 2024: 5 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 8 · 2017: 6 · 2016: 7 · 2015: 5 · 2014: 4 · 2013: 9 · 2012: 6
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Kidney Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Keywords
- erythropoietin, chronic kidney disease, arterial blood pressure, hematocrit, erythrocyte mass, vasopressors, vascular smooth muscle, vascular remodeling
- MeSH terms
- Anemia, Animals, Catecholamines, Erythrocyte Volume, Erythropoietin, Hematocrit, Humans, Hypertension, Kidney Failure, Chronic, Renin-Angiotensin System, Time Factors, Vasoconstrictor Agents, Endothelins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
